GenMark Diagnostics Inc. (NASDAQ:GNMK) shares traded down 2.7% on Wednesday . The company traded as low as $10.63 and last traded at $10.74, with a volume of 142,976 shares changing hands. The stock had previously closed at $11.04.

A number of research analysts recently weighed in on the stock. Canaccord Genuity reissued a “buy” rating and issued a $13.00 target price on shares of GenMark Diagnostics in a report on Friday, July 29th. Cowen and Company raised shares of GenMark Diagnostics from a “market perform” rating to an “outperform” rating and set a $17.00 target price for the company in a report on Friday, September 16th. Zacks Investment Research raised shares of GenMark Diagnostics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Tuesday, August 2nd. JPMorgan Chase & Co. raised their target price on shares of GenMark Diagnostics from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Friday, July 29th. Finally, Needham & Company LLC initiated coverage on shares of GenMark Diagnostics in a research note on Friday, June 17th. They set a “buy” rating and a $13.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $11.89.

The firm has a 50 day moving average of $9.14 and a 200-day moving average of $7.66. The firm’s market capitalization is $468.19 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/genmark-diagnostics-inc-gnmk-stock-price-down-2-7.html

GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Thursday, July 28th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. GenMark Diagnostics had a negative return on equity of 108.34% and a negative net margin of 101.78%. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.62 million. During the same period last year, the business posted ($0.29) EPS. The company’s revenue was up 63.6% on a year-over-year basis. Analysts predict that GenMark Diagnostics Inc. will post ($1.18) EPS for the current year.

In related news, SVP Michael Gleeson sold 7,500 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $9.00, for a total value of $67,500.00. Following the sale, the senior vice president now directly owns 246,934 shares in the company, valued at $2,222,406. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Jennifer Anne Williams sold 24,172 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, August 29th. The shares were sold at an average price of $8.63, for a total value of $208,604.36. Following the completion of the sale, the senior vice president now owns 164,937 shares in the company, valued at $1,423,406.31. The disclosure for this sale can be found here. 7.09% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of GNMK. Vanguard Group Inc. increased its stake in GenMark Diagnostics by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,641,312 shares of the company’s stock worth $14,279,000 after buying an additional 104,864 shares during the period. Turner Investments L.P. acquired a new stake in GenMark Diagnostics during the second quarter worth $218,000. I.G. Investment Management LTD. increased its stake in GenMark Diagnostics by 0.7% in the second quarter. I.G. Investment Management LTD. now owns 141,280 shares of the company’s stock worth $1,229,000 after buying an additional 1,000 shares during the period. State Board of Administration of Florida Retirement System increased its stake in GenMark Diagnostics by 4.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 17,007 shares of the company’s stock worth $148,000 after buying an additional 799 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in GenMark Diagnostics by 2.2% in the second quarter. Bank of New York Mellon Corp now owns 185,657 shares of the company’s stock worth $1,614,000 after buying an additional 3,999 shares during the period.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

5 Day Chart for NASDAQ:GNMK

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.